Teva Beats Janssen On Canadian Bortezomib Compensation
Rival To Velcade Held Up By Invalid Patents
Teva is eligible for compensation due to having been kept off the Canadian bortezomib market by Janssen suing for infringement of two patents that were subsequently found to be obvious.
You may also be interested in...
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.
The first three FDA approvals for generic fingolimod generics come amid ongoing legal uncertainty over Novartis’ Gilenya blockbuster multiple sclerosis treatment.